Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Our goal is to have a clinical trial option available for patients at every stage of disease. We offer a range of clinical trials for newly-diagnosed CLL, relapsed/refractory CLL, as well as Richter's syndrome, a condition where CLL turns into an aggressive form of lymphoma.
Newly-Diagnosed CLL
22-303: MAJIC: A phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphomaPrincipal Investigator: Matthew Davids, MD, MMSc
18-226: A phase 2 study of acalabrutinib, venetoclax, and obinutuzumab (AVO) for initial therapy of chronic lymphocytic leukemia (for patients with high-risk CLL -- deletion 17p or TP53 mutation only) Principal Investigator: Matthew Davids, MD, MMSc
Relapsed/Refractory CLL
Principal Investigator: Jennifer Crombie, MD
18-089: A phase 1/2 study of duvelisib and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma Principal Investigator: Matthew Davids, MD, MMSc
Richter’s Syndrome
16-596: CRC043: A phase 2 study of venetoclax in combination with R-CHOP for the therapy of patients with Richter’s syndrome Principal Investigator: Matthew Davids, MD, MMSc
18-089: A phase 1/2 study of duvelisib and venetoclax in patients with relapsed or refractory chronic lymphocytic lymphoma or small lymphocytic lymphoma (includes Richter's syndrome cohort)Principal Investigator: Matthew Davids, MD, MMSc
Learn more about clinical trials for CLL patients.
Translational science, which quickly moves laboratory findings into clinical practice, is also a key focus of the Center for Chronic Lymphocytic Leukemia. This includes:
Dana-Farber is currently enrolling participants for a Genetic Study of Familial Chronic Lymphocytic Lymphoma. This study, led by Jennifer R. Brown, MD, PhD, seeks to identify the genes that cause the disease, in order to develop methods of prevention and diagnosis counseling. To be eligible, participants must have at least two first-degree relatives (e.g., parent, sibling, or child) who have CLL, lymphoma, or a lymphoproliferative disorder. For more information, including detailed eligibility guidelines and participation requirements, contact lead investigator Jennifer R Brown, MD, PhD or study coordinator Conner Shaughnessy.
Learn more about the Harvard Study of Genetic Factors that Lead to Lymphoma
Jennifer Brown LabMatthew Davids LabCatherine Wu Lab
CLL Research NewsCatherine Wu, MD, comments on her latest research on CLL, including the impact of mutated SF3B1 on CLL-associated pathways.
New Patient Appointments 877-442-3324
Clinical Trials Questions?
877-DF-TRIAL (877-338-7425)
Matthew Davids, MD, MMSc, on Advances in CLL TreatmentMatthew Davids, MD, MMSc, of Dana-Farber’s Center for Chronic Lymphocytic Leukemia, shares updates on advances in treating newly-diagnosed and relapsed CLL. New approaches include ibrutinib + FCR for younger, newly-diagnosed patients and a combination of rituximab and venetoclax for relapsed patients.